Carbenicillin Phenyl

Carbenicillin Phenyl

SCHEMBL586468

CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(=O)Oc3ccccc3)c3ccccc3)C(=O)N2[C@H]1C(=O)O.[NaH]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.67
▸ RECQL P46063 4/20 0.67
▸ TDP1 Q9NUW8 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ POLB P06746 2/20 0.67
▸ MEN1 O00255 2/20 0.67
▸ HPGD P15428 1/20 0.67
▸ TEK Q02763 1/20 0.67
▸ SLC15A2 Q16348 1/20 0.67
▸ LMNA P02545 5/20 0.66
▸ TSHR P16473 1/20 0.66
▸ PTGS1 P23219 2/20 0.64
▸ RARB P10826 1/20 0.57
▸ RARG P13631 1/20 0.57
▸ NR1H2 P55055 1/20 0.57
▸ NR1H3 Q13133 1/20 0.57
▸ NR1I3 Q14994 1/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ GLA P06280 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbenicillin Phenyl SCHEMBL11475569 1.00 KDM4E (0.67) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL11308037 1.00 KDM4E (0.67) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL10734854 0.99 KDM4E (0.68) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL150616 0.99 KDM4E (0.68) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL11310099 0.99 KDM4E (0.68) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL150615 0.99 KDM4E (0.68) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL11310852 0.93 LMNA (0.64) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL11310839 0.93 LMNA (0.64) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL192220 0.91 LMNA (0.79) KDM4ERECQLTDP1KMT2APOLB
Carbenicillin Phenyl SCHEMBL11308035 0.91 LMNA (0.79) KDM4ERECQLTDP1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273712-B2 Promoting wound healing by administering a prostaglandin E and granulocyte-macrophage colony stimulating factor MEDICAL RESEARCH COUNCIL (GB) 2012-09-25 — — US claimed
US-8012967-B2 Minor groove binders UNIVERSITY OF STRATHCLYDE (GB) 2011-09-06 — — US claimed
WO-2009131692-A1 SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2009-10-29 — — WO claimed
US-20080317705-A1 Promoting Wound Healing by Administering a Prostaglandin E and Granulocyte-Macrophage Colony Stimulating Factor MEDICAL RESEARCH COUNCIL (UK) 2008-12-25 — — US claimed
CN-101326275-A Multifunctional ionic liquid composition UNIV ALABAMA (US) 2008-12-17 — — CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
EP-0786999-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1999-01-20 — — EP claimed
EP-0792371-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1998-12-30 — — EP claimed
EP-0792371-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-09-03 — — EP claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 — — EP claimed
US-5637579-A BETA-LACTAMASE INHIBITORS; BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 1997-06-10 — — US claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 — — US claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 — — WO claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 — — WO claimed
EP-0008179-A2 Powder, process for its preparation, container holding it, and syrup comprising the powder reconstituted with water BEECHAM GROUP PLC (GB) 1980-02-20 — — EP claimed
US-20250099395-A1 HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGS UNIV MARYLAND (US) 2025-03-27 — — US disclosed
EP-0227836-A1 SUSTAINED RELEASING PATCH TEIJIN LIMITED (JP) 1987-07-08 — — EP disclosed
EP-0008179-A2 Powder, process for its preparation, container holding it, and syrup comprising the powder reconstituted with water BEECHAM GROUP PLC (GB) 1980-02-20 — — EP disclosed
Send feedback